2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
Auris Medical Prices $7 Million Public Offering
12 July 2018
Auris Medical Announces Publication Confirming Dose-Dependent Effects of Betahistine and Relationship to Bioavailability in Cat Model of Acute Vertigo
03 July 2018
Auris Medical to Host Key Opinion Leader Call Focused on AM-201 Program for Treating Major Side Effects of Antipsychotics on June 11, 2018
30 May 2018
Auris Medical Provides Business and Strategy Update and Reports First Quarter 2018 Financial Results
15 May 2018
Auris Medical to Report First Quarter 2018 Financial Results and Provide Business and Strategy Update on Tuesday, May 15, 2018
14 May 2018
Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111
07 May 2018
Auris Medical Announces Publication Related to AM-111 in Peer-Reviewed Scientific Journal
04 May 2018
Auris Medical Announces Early Repayment of Part of its Loan Facility
09 April 2018
Auris Regains Compliance with Nasdaq's Minimum Bid Price Requirement
29 March 2018
Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
22 March 2018
Auris Medical Provides Business Update
13 March 2018
Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018
26 February 2018
Auris Medical Announces Extraordinary General Meeting of Shareholders
09 February 2018
Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine
07 February 2018
Auris Medical Announces Pricing of $5.5 Million Registered Direct Offering
29 January 2018
Auris Medical Provides Update on AM-111 Development Program
04 January 2018